« I am most excited to partner CERC Asia to get the Biofreedom STEMI registry. STEMI FREE would provide a great opportunity to investigate the STEMI population in Asia in a scientifically robust manner. The use of Biofreedom stent in Primary Angioplasty should be the logical next step to explore the unique Biolimus property in ACS patients and how the polymer free stent perform in “unknown bleeding risk” ACS subjects.« Paul Ong, Principal investigator of the BiofFreedom Stemi Free Registry I am looking forward to working closely with like minded investigators across Asia to run the study. The chance to make new friends and explore budding trial sites will be equally rewarding. I am very grateful for placing the trust in me. I am confident that with the expertise and support from CERC Asia we can deliver a well conducted study with robust clinical data. This is the beginning of a beautiful partnership in...
CERC was proud to organize the first ARC HBR meeting in Washington’s American College of Cardiology last Friday 13th of April...
CERC will be present at TCT Denver, Colorado, feel free to come visit us at Booth (number to be confirmed) Presentation of results : Late Breaking Trial at TCT 2017 (Colorado Convention Center, Denver, Colorado) Session : Main Arena III, Wednesday, Nov 1. Title: SENIOR: A Randomized Trial of a Bioresorbable Polymer-Based Metallic DES vs a BMS with Short DAPT in Patients With Coronary Artery Disease Older than 75 Years Date: Wednesday, November 1st, 2017 Time: 11:00:00 AM – 11:12:00...
CERC will be present at ICI Tel Aviv, feel free to come visit us at Booth (number to be...
Marie-Claure Morice will be present at ESC Congress Barcelona 2017 will do the following lecture : At 14:00 ESC Andreas Grüntzig Lecture on Interventional CardiologyThe revolution in the treatment of patients with aortic...
